Harmony Biosciences Holdings, Inc. - Common Stock (HRMY)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Mar 29, 2026Investment Snapshot
- Trading 19% below Graham Number — thin margin of safety
- Piotroski F-Score 6/9 — moderate financial health
- Strong ROE of 20.9% with 22.5% net margin
- Revenue growing at 22% annually
Harmony Biosciences Holdings, Inc. - Common Stock (HRMY) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $1.5 billion . Key value metrics: P/E ratio 8.4, P/B ratio 1.76, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Harmony Biosciences Holdings, Inc. - Common Stock — Fundamental Analysis Summary
Harmony Biosciences Holdings, Inc. - Common Stock (HRMY) is trading 19% below its Graham Number of $32.66, offering a thin margin of safety. The stock carries a low trailing P/E ratio of 8.4x.
On financial health, HRMY shows a moderate Piotroski F-Score of 6/9, and strong return on equity of 20.9% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.19.
StockPik's composite Value Score for HRMY is 100/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
HRMY reports a high gross margin of 78.7% (sector average: 33.5%) and a strong operating margin of 28.6%.
HRMY shows revenue growing at 22% year-over-year, with earnings growing at 9%.